Zhejiang Ausun - Public Comps and Valuation Multiples

Zhejiang Ausun Overview

About Zhejiang Ausun

Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.

Founded

2010

HQ

Employees

n/a

Website

ausunpharm.com

Sectors

Drug Development & Therapeutics
Small Molecules
BioTech
DeepTech

Financials

Last FY Revenue $112M

Last FY EBITDA $43.7M

EV

$1.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Zhejiang Ausun Financials

See Zhejiang Ausun valuation multiples based on analyst estimates

Zhejiang Ausun P&L

In the most recent fiscal year, Zhejiang Ausun reported revenue of $112M and EBITDA of $43.7M.

Zhejiang Ausun expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Zhejiang Ausun valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$112M	XXX	XXX	XXX
Gross Profit	XXX	$60.5M	XXX	XXX	XXX
Gross Margin	XXX	54%	XXX	XXX	XXX
EBITDA	XXX	$43.7M	XXX	XXX	XXX
EBITDA Margin	XXX	39%	XXX	XXX	XXX
EBIT	XXX	$28.9M	XXX	XXX	XXX
EBIT Margin	XXX	26%	XXX	XXX	XXX
Net Profit	XXX	$29.0M	XXX	XXX	XXX
Net Margin	XXX	26%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Zhejiang Ausun including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Zhejiang Ausun achieved $112M in revenue and $43.7M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$112M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$60.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	54.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$43.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	39.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$28.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	25.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$29.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	26.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Zhejiang Ausun

This financial data table provides comprehensive performance metrics for Zhejiang Ausun, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Zhejiang Ausun reported $112M in total revenue.
Fiscal year EBITDA was $43.7M.
The company maintained a gross profit margin of 54.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 39.2%.
Net profit margin reached 26.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Zhejiang Ausun. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Zhejiang Ausun Stock Performance

Zhejiang Ausun has current market cap of CNY 8.5B (or $1.2B), and EV of CNY 7.7B (or $1.1B).

Market Cap Evolution

Zhejiang Ausun Stock Data

As of October 17, 2025, Zhejiang Ausun's stock price is CNY 10 (or $1).

See Zhejiang Ausun trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.1B	$1.2B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Zhejiang Ausun Valuation Multiples

Zhejiang Ausun's trades at 9.6x EV/Revenue multiple, and 24.6x EV/EBITDA.

See valuation multiples for Zhejiang Ausun and 15K+ public comps

Zhejiang Ausun Financial Valuation Multiples

As of October 17, 2025, Zhejiang Ausun has market cap of $1.2B and EV of $1.1B.

Equity research analysts estimate Zhejiang Ausun's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Zhejiang Ausun's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.2B	XXX	$1.2B	XXX	XXX	XXX
EV (current)	$1.1B	XXX	$1.1B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	9.6x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	24.6x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	37.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	41.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	114.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Zhejiang Ausun Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Zhejiang Ausun Margins & Growth Rates

Zhejiang Ausun's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Zhejiang Ausun's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Zhejiang Ausun's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Zhejiang Ausun and other 15K+ public comps

Zhejiang Ausun Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	9%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	39%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	28%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial